U.S. Food and Drug Administration (FDA)

Emergency Response Authorities and Access to Medical Countermeasures

February 10, 2021

Brooke Courtney, JD, MPH
Andrea Gormley, PharmD, JD

For the audio portion of this presentation, dial 1-888-455-5125 and enter pass code 4495815. Slides from today’s presentation will be available in CDC’s Online Technical Resource and Assistance Center (On-TRAC).
CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
Please Note

- All audio lines are automatically muted
- Post your questions anytime through chat box
- Participate in our interactive polling questions
- This is being recorded and will be posted in On-TRAC
- Try our audio call-in number if experiencing audio problems via Adobe Connects
Purpose

- Provide an overview of FDA’s tools and authorities for facilitating the availability of medical countermeasures (MCMs) for emergency preparedness and response.

- Provide an overview of FDA’s response to COVID-19, focusing on Emergency Use Authorizations (EUAs).

- Provide web links to MCM-related resources.
Presenters

Brooke Courtney, JD, MPH
Senior Regulatory Counsel
Office of Counterterrorism and Emerging Threats (OCET),
Office of the Commissioner

Andrea Gormley, PharmD, JD
Associate Director for Regulatory Affairs
Counterterrorism and Emergency Coordination Staff (CTECS),
Center for Drug Evaluation and Research (CDER)
Webinar Outline

- Emergency Use Authorization (EUA) Authority
  - Overview of FDA’s COVID-19 Response

- Other Emergency Use Authorities for Approved MCMs:
  - Emergency Dispensing Orders
  - Emergency Use Instructions
  - Expiration Dating Extensions
  - Waivers of current Good Manufacturing Practice (cGMP) Requirements

- Liability Protections: PREP Act

- Resources
Subtopic 1

Emergency Use Authorization (EUA) Authority
What is a medical countermeasure (MCM)?

- During public health emergencies, MCMs may be needed to prevent or treat diseases or conditions caused by chemical, biological, radiological, or nuclear (CBRN) or emerging infectious disease threats, like pandemic influenza, Zika virus, and SARS-CoV-2

- FDA is responsible for reviewing the safety and effectiveness of MCMs—including drugs, therapeutic biologics, vaccines, and devices, such as diagnostic tests—to counter these threats

- MCMs include:
  - Qualified countermeasures as defined in section 319F–1(a)(2)(A) of the Public Health Service Act (PHS Act) (42 USC. § 247d–6a(a))(2)(A)
  - Qualified pandemic or epidemic products as defined in section 319F–3(i)(7) of the PHS Act (42 USC. § 247d–6d(i)(7))
  - Security countermeasures as defined in section 319F-2(c)(1)(B) of the PHS Act (42 USC § 247d–6b(c)(1)(B))
What if an MCM is needed for use during a response before it’s been approved by FDA?

- **Goal**: FDA approval before stockpiling and use during a response

- But that is not always possible. For example:
  - There might not be any approved products for the threat or condition
  - An approved product might need to be used in unapproved ways (e.g., in a new age group; for a new threat or condition; without an individual prescription)
  - There might be supply shortages of an approved product
  - Clinical trial environment might not be practical

- **Expanded access mechanisms** (FD&C Act §§ 561)
  - Investigational New Drug application (IND) (21 CFR Part 312)
  - Investigational Device Exemption (IDE) (21 CFR Part 812)

- **Emergency use mechanisms**
  - Emergency Use Authorization (EUA) (FD&C Act § 564)
  - Other emergency use authorities (FD&C Act §§ 564A, 564B)
Emergency Use Authorization (EUA)

- Established by Project BioShield Act of 2004; authority delegated to the Commissioner of Food and Drugs (FDA)

- Amended by:
  - PAHPRA (2013) (to provide additional pre-event flexibilities, among other things)
  - 21st Century Cures Act (2016) (to add animal drugs)
  - P.L. 115-92 (2017) (to provide additional flexibilities for DoD)

- Part of the post-9/11 Federal Government focus on MCM stockpiling and preparedness for counterterrorism
  - Provided physicians and public health officials an “important new tool” for public health and medical care under emergency conditions

- Recognition there will always be promising new drugs, biological products, and devices in the pipeline, as well as promising investigational uses

https://wwwnc.cdc.gov/eid/article/13/7/06-1188_article
Emergency Use Authorization (EUA)

- What is an EUA?
  - A legal mechanism FDA can use to facilitate access to critical medical products during certain defined emergency events

- With an EUA, FDA can authorize for use in emergencies involving a CBRN agent(s) [and, for DoD, an agent or agents that may cause, or are otherwise associated with, an imminently life-threatening and specific risk to United States military forces] the:
  - Use of unapproved MCMs or
  - Unapproved use of approved MCMs (e.g., for a new indication, such as amoxicillin for anthrax)


Emergency Use Authorization (EUA)

- When scientific evidence is available to support MCM use in a CBRN emergency, issuing an EUA enables response stakeholders to use, or prepare to use, an MCM without violating provisions of the FD&C Act.

- Requested by government (e.g., CDC, ASPR, DoD) or industry sponsors; FDA may prioritize requests if needed.

- Can help to ensure availability of applicable PREP Act liability protections.

- Materials (e.g., letter of authorization, fact sheets) may be amended/reissued after initial issuance if needed.

- Before FDA issuance, multiple steps with other government partners are required (as outlined on the next slide).
Summary of EUA Issuance Process

In the case of a DOD determination, the HHS Secretary shall determine within 45 days whether to issue an EUA declaration.

HHS SECRETARY
Declaration that Circumstances Exist Justifying the EUA

FDA COMMISSIONER
Issuance of EUA (if criteria for issuance met)

Termination of Declaration & EUA

Consultation with ASPR, CDC, NIH
Example of EUA Issuance Process: COVID-19 Vaccine

- **2/4/20:** HHS issued an EUA determination
  - Pursuant to Section 564(b)(1)(C) of the FD&C Act, the Secretary of HHS determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19

- **3/27/20:** HHS issued an EUA declaration for drugs and biological products
  - On the basis of the 2/4/20 HHS EUA determination, the Secretary of HHS declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the FD&C Act, subject to terms of any authorization issued under that section

- **12/18/20:** FDA issued an EUA for Moderna’s COVID-19 vaccine
  - Issuance based on the above determination and declaration
EUA Criteria for Issuance and Conditions

- **Criteria for issuance**: Based on the totality of scientific evidence available to FDA —
  - Serious or life-threatening illness/condition caused by the agent(s) referred to in the HHS Secretary’s EUA declaration
  - Reasonable belief the product “may be effective” in preventing, diagnosing, or treating serious or life-threatening diseases or conditions caused by the agent(s)
  - Known/potential benefits outweigh known/potential risks
    - Provides for a lower level of evidence than the "effectiveness" standard FDA uses for product approvals
    - Case-by-case: Recommended safety and effectiveness data requirement can vary depending on the nature of the emergency and product candidate
  - No adequate, approved, and available alternative to the product

- **Conditions of authorization**: Safeguards specific to each EUA are required, some are discretionary to protect the public
FDA Review of EUA Requests

- FDA review timelines and action on an EUA request depend on:
  - The product profile – What product data are available to support a risk/benefit analysis?
  - The existence, if any, of pending applications (i.e., IND, pre-EUA) for the product – What does FDA already know about the product?
  - The nature of the emergency – How imminent is the threat?
  - Other relevant factors – Product data in related disease states, safety information?

- Although the time required for FDA action will vary, in an emergency situation that is occurring or believed imminent, a request for consideration for an EUA could be acted upon within a matter of hours or days
What’s typically included in an EUA package?

- Letter of authorization
  - Addressed to the EUA requester (e.g., the ASPR; the CEO of a diagnostic company); signed by FDA’s Chief Scientist
  - Includes the scope of authorization [e.g., “for the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age] and conditions (e.g., reporting of adverse events)

- Fact Sheet for Healthcare Providers

- Fact Sheet for Recipients and Caregivers

- Instructions for use (if applicable)

- Other labeling, review memo, etc. (if applicable)

Subtopic 2

Overview of FDA’s Response to COVID-19
Overview of FDA’s COVID-19 Response Roles

- Engaging and collaborating with interagency and SLTT partners
- Monitoring for fraudulent product, halting the sale of products with fraudulent claims related to COVID-19
- Actively monitoring medical and food product supply chains
- Facilitating the development of diagnostics, vaccines, and therapeutics
- Approving medical products
- Monitoring for adverse events
- Issuing guidance documents for regulated industry
- Public communications
- Facilitating imports of medical products needed for the response (e.g., PPE)
- Facilitating access to MCMs, including through issuing EUAs
- etc...
Early COVID-19 Response – Access to Treatment

- Expanded Access (21 CFR 312):
  - Use of an investigational drug outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition
  - No comparable or satisfactory alternative treatment options

- In the early days of the COVID-19 response, CDER was receiving a large number of requests for use of investigational treatment products under expanded access
  - To manage the large volume of requests (particularly for remdesivir), CDER established a 24/7 call center

- Issuance of EUA streamlined the large scale patient access to investigational treatment
Overview of COVID-19 Response EUAs (January 19, 2021)

- **Therapeutics:** 8 EUAs for products to treat COVID-19 and serious conditions caused by COVID-19
  - One treatment (remdesivir) is currently approved by the FDA for use in COVID-19
  - Hydroxychloroquine/chloroquine, remdesivir, monoclonal antibodies, convalescent plasma, supportive care (intubation, dialysis)

- **Devices:**
  - *Testing:* 319 tests & sample collection devices authorized under EUAs
  - *Other:* EUAs for PPE, blood purification devices, PPE decon systems, infusion pumps, ventilators/ventilator accessories, etc.

- **Vaccines:** 2 EUAs issued for COVID-19 vaccines (Pfizer & Moderna)


Reference: [https://www.fda.gov/media/137005/download](https://www.fda.gov/media/137005/download)
COVID-19 Response – Guidance Development

- The FDA has issued more than 70 guidance documents to provide updated policies, transparency, and regulatory flexibility on:
  - Diagnostics, personal protective equipment, other medical devices, investigational treatment with convalescent plasma, conduct of clinical trials of medical products, blood supply, hand sanitizers, food safety and supply, telemedicine and other topics.

- COVID-19 Guidance Website
Examples of Other FDA COVID-19 Response Activities

- Fraudulent products – 1281 fraudulent products identified, FDA issuing warning letters and alerting marketplaces
- Hand Sanitizers – issued policy for methanol testing and maintain a [website of “do not use” hand sanitizers](#)
- [COVID-19 Resources for Health Professionals](#) provides quick and easy access to FDA information for health care professionals.
- Translations of vaccine EUA Fact Sheets into multiple languages
- [COVID-19 FAQs](#) (Spanish version available)
  - Hand sanitizers, testing, PPE, food safety, animal food safety
- etc.
Subtopic 3

Other Emergency Use Authorities for Approved MCMs:
Emergency Dispensing Orders, Emergency Use Instructions, Expiry Dating Extensions
Other MCM Emergency Use Authorities

- During emergency responses, certain uses of approved medical products may be needed to achieve critical public health goals, but could violate provisions of the FD&C Act, for example:
  - Dispensing a drug product beyond its labeled expiration date
  - Giving recipients of a vaccine simplified fact sheets about the product that are not part of its FDA-approved labeling

- Section 564A of the FD&C Act (PAHPRA, 2013)
  - Emergency dispensing orders
  - Expiry dating extensions
  - Emergency use instructions
  - Waivers of certain cGMP and REMS requirements

- Section 564B of the FD&C Act (PAHPRA, 2013)
  - To allow for holding/stockpiling of unapproved product
Emergency Dispensing Orders

- Established by PAHPRA (2013), this authority allows FDA to facilitate the availability and use of eligible, approved MCMs needed during public health emergencies without FDA needing to issue an EUA [FD&C Act § 564A(d)]

- FDA may allow emergency dispensing [including mass dispensing at a point of dispensing (POD)] of approved MCMs during an actual CBRN emergency, without requiring an individual prescription for each recipient of the MCM, if
  - (1) permitted by state law or
  - (2) in accordance with an order issued by FDA
Emergency Dispensing Orders in the Field

- To date, FDA has issued two (2) emergency dispensing orders:
  - Doxycycline for inhalational anthrax PEP (2016)
  - Ciprofloxacin for inhalational anthrax PEP (2016)

- In the above orders, the term “stakeholder(s)” is defined as the public agency or its delegate that has legal responsibility and authority for responding to an incident, based on political or geographical boundary lines (e.g., city, county, tribal, State, or Federal), or functional (e.g., law enforcement or public health range) or sphere of authority to prescribe, administer, deliver, distribute, or dispense oral doxycycline products in an emergency situation

- FDA worked closely with CDC on these orders and in the development of the CDC-issued emergency use instructions (EUI) that accompany them
Emergency Use Instructions (EUI)

- Established by PAHPRA (2013), this authority allows CDC to facilitate the availability of streamlined information about the use of eligible, approved MCMs needed during public health emergencies without FDA needing to issue an EUA (FD&C Act § 564A(e))

- Authority was delegated to the CDC Director (2013); when feasible, FDA and CDC will coordinate issuance of an emergency dispensing order and EUI for an MCM
  - An FDA-CDC MOU was developed to guide interactions when CDC calls upon FDA to review EUI

- CDC may create and issue, and government stakeholders may disseminate, EUI (also referred to as fact sheets for recipients of an MCM and for health care professionals) about the FDA-approved conditions of use for such MCMs before or during a CBRN event
Excerpt of EUI for Ciprofloxacin for Post-Exposure Prophylaxis (PEP) of Anthrax

Emergency Use Instructions for Healthcare Providers

This fact sheet provides instructions for the use of ciprofloxacin for post-exposure prophylaxis (PEP) during an emergency involving anthrax (referred to as Emergency Use Instructions (EUI) fact sheet). Ciprofloxacin is FDA-approved for PEP of inhalation anthrax – to reduce the incidence or progression of disease following exposure to aerosolized *Bacillus anthracis* (*B. anthracis*). The Food and Drug Administration (FDA) has also issued an order permitting the emergency dispensing of oral formulations of ciprofloxacin without a prescription during an anthrax emergency to individuals who may have been exposed to *B. anthracis*.

What is inhalation anthrax?

Anthrax is a serious disease caused by the spore-forming bacterium *B. anthracis*. Inhalation anthrax is the most deadly form of the disease, with a historical mortality rate of approximately 90% for untreated cases. Inhalation anthrax occurs when an individual inhales aerosolized spores. It is not spread from person to person. Early symptoms include fever, chills, fatigue, cough or headache. Later symptoms include shortness of breath, chest pain, confusion or nausea. Symptoms usually occur within 7 days of inhaling anthrax spores, but can
EUI Instructions for Making Doxy Suspension from Tablets

A. Get the supplies you need

You will need these items to make doses of doxycycline for children and adults who cannot swallow pills:

- 1 doxycycline hyclate tablet (100 mg)
- 1 metal teaspoon
- 1 oral syringe or medicine spoon (if available)
- 2 small bowls
- Small amount of drinking water (4 teaspoons or 20 mL)
- 1 of these foods or drinks to make the crushed doxycycline taste better
  - Milk, including breast milk and formula for infants
  - Chocolate milk
  - Chocolate pudding
  - Apple juice mixed with 2 to 4 teaspoons of sugar

B. Soak the tablet in water and crush it

1. Put 1 doxycycline hyclate tablet in a small bowl.
2. Add 4 teaspoons (20 mL) of water to the same bowl.
3. Let the tablet soak in the water for at least 10 minutes to soften it.
4. Crush the tablet with the back of the metal spoon until you can't see any pieces of the tablet in the water.
5. Stir the tablet and water to mix it well.

You have now made the doxycycline and water mixture.

C. Measure the right amount of Doxycycline

1. Find your child's weight on the chart below. Weight is better, but if you don't know how much your child weighs, find your child's age on the chart.
2. Follow the row of your child's weight or age across to the column "Amount of Doxycycline & Water Mixture to Measure.*"
3. Measure the amount of doxycycline and water mixture for your child's weight or age from the first bowl.
   - For a one-half (1/2) teaspoon dose, fill the teaspoon halfway or use an oral syringe if available. It is better to give a little more of the medicine than not enough.
4. Place this amount into the second bowl. This is one dose that should be mixed with food or drink.

D. Mix the dose with food or drink

- Mix the dose (measured amount of doxycycline and water mixture) in the second bowl with 3 teaspoons of one of the following:
  - Milk, including breast milk and formula for infants
  - Chocolate milk
  - Chocolate pudding
  - Apple juice mixed with 2 to 4 teaspoons of sugar

You now have one dose, mixed with food or drink.

E. Give the dose

- Give your child all of the doxycycline, water and food mixture from the second bowl. Make sure your child swallows all of it. This is one dose.
- Do this once every 12 hours (once in the morning and once at night) each day for as long as directed.
Expiration Dating Extensions

- To help prepare for public health emergencies, MCMs may be stockpiled by federal or SLTT governments and even by some private sector partners.

- A medical product is typically labeled by the manufacturer with an expiration date. This reflects the time period during which the product is expected to remain stable, or retain its identity, strength, quality, and purity, when it is properly stored according to its labeled storage conditions.

- In some cases, testing has shown that certain properly stored medical products can be used beyond their labeled expiration date if they retain their stability. Recognizing stakeholders’ MCM stockpiling challenges, FDA is engaged, when appropriate, in various expiration dating extension activities:
  - Initiated by the manufacturer
  - Shelf-Life Extension Program (SLEP)
  - Emergency use authorities
  - Enforcement discretion
Shelf-Life Extension Program (SLEP)

- SLEP is a federal program for extending the useful life of certain federally-stockedpile medical products (not available for SLTT partners)
  - MCMs that are owned by components of DoD or other federal program participants such as the Strategic National Stockpile (SNS)

- SLEP is designed to defer drug replacement costs for date-sensitive stockpiles of drugs by extending their useful shelf life beyond the manufacturer’s original labeled expiration date
  - FDA laboratory personnel test drugs to assure stability and quality before an expiry dating extension is granted

- In FY 2019, FDA granted shelf-life extensions for approximately 2,000 lots (batches) of MCM drugs
Expiration Dating Extension Authority Example: Doxycycline Shelf Life Extension

- In response to 2011-2013 rising doxycycline pricing as well as stakeholders’ overarching concerns about being able to replace existing stockpiles, FDA developed a guidance where state and local stockpilers can test doxycycline product and submit test results to FDA to support an FDA decision about extending its useful shelf life, thereby deferring replacement costs
  - Section 564A(b) of the FD&C Act
  - Doxycycline Shelf Life Extension Guidance
  - Current Doxycycline Expiration Extensions (to July 2022)
    - Extrapolation to others properly holding the same lots

- Based on government stakeholder needs, FDA continues to review scientific data to determine whether additional extensions of other MCMs may be supported outside of SLEP

Waivers of Certain cGMP and REMS Requirements

- Under Section 564A(c) of the FD&C Act, FDA may waive otherwise applicable manufacturing requirements [current Good Manufacturing Practices (cGMPs)], such as storage or handling, to accommodate emergency response needs
  - Examples:
    - Doxycycline and ciprofloxacin emergency dispensing orders (defined temporary storage temperature deviations during an anthrax response)
    - To facilitate access to certain ventilators during the COVID-19 response

- Under Section 505-1 of the FD&C Act, the waiver authority for risk evaluation and mitigation strategies (REMS) encompasses any element for MCMs to mitigate the health effects of a CBRN emergency
Subtopic 4
Liability Protections:
Public Readiness and Emergency Preparedness (PREP) Act
PREP Act (2005)

- An HHS (not FDA) authority; a PREP Act declaration is specifically for the purpose of providing immunity from liability, and is different from, and not dependent on, other emergency declarations.

- Authorizes the Secretary of HHS to issue a PREP Act declaration, which provides immunity from liability (except for willful misconduct) for claims:
  - of loss caused, arising out of, relating to, or resulting from administration or use of countermeasures to diseases, threats, and conditions
  - determined by the Secretary to constitute a present, or credible risk of a future public health emergency
  - to entities and individuals involved in the development, manufacture, testing, distribution, administration, and use of such countermeasures

- Immunity is not available for:
  - Death or serious physical injury caused by willful misconduct
  - Foreign claims where the U.S. has no jurisdiction
PREP Act

- “Covered countermeasures”
  - Types are defined in law (e.g., “qualified pandemic or epidemic product”)
  - Include medical products that are approved or authorized for emergency use (under EUA, IND/IDE, other emergency use authorities; NIOSH-cleared respirators for COVID)

- Established the Countermeasures Injury Compensation Program (CICP) for product-related injuries (42 CFR part 110)
  - For “serious physical injuries”; payer of last resort
  - Funds must be appropriated by Congress
    - https://www.hrsa.gov/cicp/

- Additional information:
  - Questions about the PREP Act should be directed to HHS
    - https://www.phe.gov/Preparedness/legal/prepact/Pages/default.aspx
PREP Act Declarations Issued

• Anthrax medical countermeasures
• Acute radiation syndrome medical countermeasures
• Botulinum toxin medical countermeasures
• Medical countermeasures against COVID-19
• Ebola disease therapeutics
• Ebola disease vaccines
• Marburgvirus and/or Marburg disease countermeasures
• Nerve agents and certain insecticides countermeasures
• Pandemic influenza medical countermeasures
• Smallpox medical countermeasures
• Zika virus vaccines
Available Resources
Resources


- EUA (FDA)


- PREP Act (HHS): [https://www.phe.gov/Preparedness/legal/prepact/Pages/default.aspx](https://www.phe.gov/Preparedness/legal/prepact/Pages/default.aspx)
Questions

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Please send your suggestions for future webinar topics to:
preparedness@cdc.gov